Neurology

Daily Life and Symptom Management in SPMS

At a Glance

Daily SPMS care focuses on preserving independence and quality of life through individualized rehabilitation, pacing for fatigue, bladder evaluation and treatment, annual cognitive monitoring, and support for mood changes. Work with a team of specialists to tailor these strategies to your symptoms.

Living with Secondary Progressive Multiple Sclerosis (SPMS) requires a shift from simply managing “attacks” to proactively supporting your body’s daily functions. Because SPMS involves a gradual accumulation of symptoms like fatigue, mobility changes, and bladder issues, the most effective care comes from a multidisciplinary team. This team often includes your neurologist, physical therapist, urologist, and occupational therapist working together to protect your quality of life ^[1]^[2].

Managing Mobility and Spasticity

Mobility challenges are nearly universal in SPMS, but they can be managed through a combination of technology and targeted exercise ^[3].

Physical Therapy: Regular sessions are essential for maintaining muscle strength and flexibility. Robot-assisted gait training (using advanced machines to help you walk) is an emerging option that can help improve walking patterns for those with more significant mobility needs ^[4].
Spasticity: This refers to the stiffness or “tightness” in your muscles. Standard treatments include oral medications like baclofen, but for more localized stiffness, your doctor may recommend botulinum toxin (Botox) injections directly into the affected muscles to help them relax.

Fighting Fatigue and Protecting the Brain

Fatigue is one of the most burdensome symptoms of SPMS, affecting over 75% of patients ^[3].

Investigational Supplements (Alpha-Lipoic Acid): You may read about alpha-lipoic acid. A small pilot study showed it reduced the rate of brain atrophy (shrinkage) compared to a placebo ^[5]. However, it is not an established or approved SPMS treatment, and the trial did not definitively prove it improves walking or disability ^[6]. High-dose supplements can have adverse effects; always discuss them with your clinician or pharmacist before use.
Dietary Shifts: Preliminary studies suggest that certain dietary patterns may help reduce the “fatigue impact” and improve quality of life, though no specific diet has been proven to stop the disease from progressing ^[7].
Energy Conservation: Occupational therapists can teach you “pacing” techniques—learning how to bank your energy so you can accomplish the tasks that matter most to you without becoming overwhelmed by fatigue.

Proactive Bladder Care

In SPMS, bladder issues can cause significant distress and increase the risk of recurrent infections ^[8].

Screening and PVR: If you have risk factors, recurrent urinary tract infections (UTIs), or specific neurologic findings, your doctor may order a Post-Void Residual (PVR) test, usually done via a quick ultrasound, to see if your bladder is emptying completely ^[9]^[10]. It is a highly useful tool to guide treatment, though routine screening for every asymptomatic person varies by clinic.
Medication Options: Mirabegron is a medication that helps the bladder hold more urine. It may have a lower risk of causing “brain fog” or cognitive side effects compared to older antimuscarinic medications ^[11]^[12]. However, mirabegron can affect blood pressure and interact with other medications, so its use must be individualized.
Advanced Treatments: If oral medications aren’t enough, intradetrusor botulinum toxin A (Botox injected into the bladder wall) can significantly reduce incontinence. However, this carries a risk—a notable percentage of patients may temporarily or long-term need to use a catheter to empty their bladder after the procedure, depending on dose and baseline function ^[13]^[14].

Cognitive Health and Annual Tracking

Physical disability does not always mirror cognitive disability. You may find that while your walking is stable, your “processing speed”—how fast you can think or react—has slowed down ^[3]^[15].

Annual SDMT: The Symbol Digit Modalities Test (SDMT) is a widely used screening tool for tracking cognitive health in MS. Consensus guidelines recommend having this test at least once a year to look for changes ^[16]^[17].
Understanding the Results: A drop of about 4 to 8 points on this test is sometimes considered a marker of change, but this is highly individualized (accounting for age, education, and fatigue) and should prompt a broader conversation or formal neuropsychological assessment, rather than an automatic treatment change ^[18]^[19]. Be aware that you might score slightly better the second time you take the test simply because you’ve seen it before (the “practice effect”) ^[20].
Mental Health: Anxiety and depression affect nearly 40% of people with SPMS ^[3]. These are common, treatable, and multifactorial in MS, and can significantly worsen your fatigue and walking speed if left untreated ^[15].

Common questions in this guide

How can I manage walking problems and muscle stiffness in SPMS?

A physical therapist can help maintain strength, flexibility, and safe walking, and robot-assisted gait training may be considered when mobility needs are greater. Baclofen may help more widespread stiffness, while botulinum toxin injections can target specific tight muscles. Your care team can tailor the plan to your symptoms and goals.

When should I have a PVR test for SPMS bladder symptoms?

A post-void residual, or PVR, test uses a quick ultrasound to measure how much urine remains after you urinate. It may be recommended for bladder-emptying symptoms, recurrent urinary tract infections, certain risk factors, or neurologic findings; routine testing is not necessarily needed for every person without symptoms.

Is mirabegron a good option for bladder problems in SPMS?

Mirabegron helps the bladder store more urine and may cause fewer thinking-related side effects than some older bladder medicines. It can affect blood pressure and interact with other medicines, so a clinician should review your blood pressure and medication list.

What are the risks of bladder Botox in SPMS?

Botulinum toxin injected into the bladder wall can reduce incontinence when oral medicines are not enough. Some people temporarily or longer term need a catheter to empty the bladder afterward, with risk depending on the dose and baseline bladder function.

How is cognitive change monitored in SPMS?

The Symbol Digit Modalities Test, or SDMT, is commonly used at least once a year to track processing speed. A decline of about 4 to 8 points may signal change, but age, education, fatigue, and the possibility of scoring better after repeated exposure all matter, so one result does not automatically require a treatment change.

Can alpha-lipoic acid treat SPMS?

Alpha-lipoic acid is not an established or approved treatment for SPMS. A small pilot study suggested it might slow brain shrinkage, but it did not prove benefits for walking or disability; high doses may cause adverse effects and should be discussed with a clinician or pharmacist.

What daily strategies can help with SPMS fatigue?

An occupational therapist can teach pacing and energy-conservation techniques, such as planning activities and resting before exhaustion. Dietary patterns may help fatigue impact or quality of life for some people, but no specific diet has been proven to stop SPMS progression.

Get notified when new evidence is published on secondary progressive multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

SPMS symptom management is individualized and may combine neurology, physical therapy, occupational therapy, and urology care to preserve function and quality of life.
Physical therapy, gait training, pacing, and energy-conservation techniques can support mobility and reduce fatigue, but no specific diet has been proven to stop SPMS progression.
PVR testing can assess bladder emptying when symptoms, recurrent urinary tract infections, risk factors, or neurologic findings make it appropriate.
Annual SDMT testing can track cognitive processing speed, but score changes require context and may lead to neuropsychological assessment rather than an automatic treatment change.
Mirabegron and botulinum toxin may help bladder symptoms, while baclofen or targeted botulinum toxin may help spasticity; blood-pressure effects and catheter needs should be discussed before treatment.

References (20)

1
Progressive Multiple Sclerosis.
Willis MA, Fox RJ
Continuum (Minneapolis, Minn.) 2016; (22(3)):785-98 doi:10.1212/CON.0000000000000323.
PMID: 27261682
2
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Ziemssen T, Bhan V, Chataway J, et al.
Neurology(R) neuroimmunology & neuroinflammation 2023; (10(1)) doi:10.1212/NXI.0000000000200064.
PMID: 36414428
3
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.
Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, et al.
Multiple sclerosis and related disorders 2024; (90()):105787 doi:10.1016/j.msard.2024.105787.
PMID: 39142050
4
Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany.
Solari A, Giovannetti AM, Giordano A, et al.
Frontiers in neurology 2019; (10()):916 doi:10.3389/fneur.2019.00916.
PMID: 31507519
5
Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.
Spain R, Powers K, Murchison C, et al.
Neurology(R) neuroimmunology & neuroinflammation 2017; (4(5)):e374 doi:10.1212/NXI.0000000000000374.
PMID: 28680916
6
Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis.
Loy BD, Fling BW, Horak FB, et al.
Complementary therapies in medicine 2018; (41()):169-174 doi:10.1016/j.ctim.2018.09.006.
PMID: 30477834
7
Effects of Dietary Modification Based on Complementary and Alternative Iranian Medicine in Patients with Secondary-Progressive Multiple Sclerosis: A Randomized Controlled Clinical Trial.
Moravejolahkami AR, Hadi S, Hadi V, et al.
Journal of integrative and complementary medicine 2023; (29(11)):747-756 doi:10.1089/jicm.2023.0037.
PMID: 37307014
8
Neurourological assessment in people with multiple sclerosis (MS): a new evaluated algorithm.
Domurath B, Kurze I, Kirschner-Hermanns R, et al.
Multiple sclerosis and related disorders 2020; (44()):102248 doi:10.1016/j.msard.2020.102248.
PMID: 32562907
9
Neurogenic Lower Urinary Tract Dysfunction in Asymptomatic Patients with Multiple Sclerosis.
Jaekel AK, Winterhagen FI, Zeller FL, et al.
Biomedicines 2022; (10(12)) doi:10.3390/biomedicines10123260.
PMID: 36552016
10
Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.
Medina-Polo J, Adot JM, Allué M, et al.
Neurourology and urodynamics 2020; (39(2)):762-770 doi:10.1002/nau.24276.
PMID: 31943361
11
Perspectives on urological care in multiple sclerosis patients.
Moussa M, Abou Chakra M, Papatsoris AG, et al.
Intractable & rare diseases research 2021; (10(2)):62-74 doi:10.5582/irdr.2021.01029.
PMID: 33996350
12
An individual participant meta-analysis of mirabegron in multiple sclerosis and spinal cord injury.
Welk B, Krhut J, Sýkora R
Neurourology and urodynamics 2024; (43(4)):803-810 doi:10.1002/nau.25439.
PMID: 38477368
13
Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.
Tullman M, Chartier-Kastler E, Kohan A, et al.
Neurology 2018; (91(7)):e657-e665 doi:10.1212/WNL.0000000000005991.
PMID: 30030330
14
Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.
Kaviani A, Khavari R
The Urologic clinics of North America 2017; (44(3)):463-474 doi:10.1016/j.ucl.2017.04.012.
PMID: 28716326
15
Patient reported outcomes in a secondary progressive MS cohort related to cognition, MRI and physical outcomes.
Theodorsdottir A, Nielsen HH, Ravnborg MH, Illes Z
Multiple sclerosis and related disorders 2023; (71()):104550 doi:10.1016/j.msard.2023.104550.
PMID: 36842312
16
Recommendations for cognitive screening and management in multiple sclerosis care.
Kalb R, Beier M, Benedict RH, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) 2018; (24(13)):1665-1680 doi:10.1177/1352458518803785.
PMID: 30303036
17
[Neuropsychological and MRI diagnostics in secondary progressive multiple sclerosis].
Penner IK, Gass A, Schreiber H, Wattjes MP
Der Nervenarzt 2021; (92(12)):1293-1301 doi:10.1007/s00115-021-01118-9.
PMID: 33891150
18
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
Weinstock Z, Morrow S, Conway D, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) 2022; (28(7)):1101-1111 doi:10.1177/13524585211049397.
PMID: 34612114
19
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.
Benedict RH, DeLuca J, Phillips G, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(5)):721-733 doi:10.1177/1352458517690821.
PMID: 28206827
20
Repeated forms, testing intervals, and SDMT performance in a large multiple sclerosis dataset.
Fuchs TA, Gillies J, Jaworski MG, et al.
Multiple sclerosis and related disorders 2022; (68()):104375 doi:10.1016/j.msard.2022.104375.
PMID: 36544304

This page explains daily symptom management in SPMS for educational purposes and does not replace medical advice. Discuss bladder testing, medicines, rehabilitation, cognitive changes, and supplements with your neurologist and care team.

Guide Contents